Overview

Swallowing Outcomes and Circulating Tumor DNA in Patients With HPV Related Oropharyngeal Cancer Treated With Transoral Surgery and Reduced Intensity Adjuvant Therapy

Status:
Not yet recruiting

Trial end date:
2022-12-30

Target enrollment:

Participant gender:

Summary

This is a non-randomized, open-label phase II clinical trial that studies the effect of reduced dose radiation therapy and chemotherapy after surgery in treating patients with human papillomavirus (HPV) caused throat cancer. Giving reduced dose radiation therapy and chemotherapy after surgery may improve quality of life compared with standard of care primary chemoradiation approach without compromising survival.

Phase:

Phase 2

Details

Lead Sponsor:

Rutgers, The State University of New Jersey

Collaborator:

National Cancer Institute (NCI)

Treatments:

Cisplatin